WO2003015820A1 - Medicaments combines d'agoniste de la gnrh - Google Patents

Medicaments combines d'agoniste de la gnrh Download PDF

Info

Publication number: WO2003015820A1
Authority: WO; WIPO (PCT)
Prior art keywords: gnrh agonist; drugs; qol; preventive; combination drugs
Prior art date: 2001-08-10

Application number

PCT/JP2002/008130

Other languages

English (en)

French (fr)

Inventor

Shuichi Furuya

Masami Kusaka

Original Assignee

Takeda Chemical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-10

Filing date

2002-08-08

Publication date

2003-02-27

2002-08-08 Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.

2002-08-08 Priority to DE60239207T priority Critical patent/DE60239207D1/de

2002-08-08 Priority to US10/486,095 priority patent/US20050215528A1/en

2002-08-08 Priority to AT02758814T priority patent/ATE498408T1/de

2002-08-08 Priority to EP02758814A priority patent/EP1424080B1/en

2002-08-08 Priority to CA2458452A priority patent/CA2458452C/en

2003-02-27 Publication of WO2003015820A1 publication Critical patent/WO2003015820A1/ja

2007-03-27 Priority to US11/727,549 priority patent/US20070179097A1/en

2010-05-07 Priority to US12/662,866 priority patent/US20100286063A1/en

Links

NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 title abstract 4
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 title abstract 4
239000000556 agonist Substances 0.000 title abstract 4
229940000425 combination drug Drugs 0.000 title abstract 2
239000003814 drug Substances 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000003449 preventive effect Effects 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 1
102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 1
229940127394 Sex Hormone Synthesis Inhibitors Drugs 0.000 abstract 1
230000004097 bone metabolism Effects 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000849 selective androgen receptor modulator Substances 0.000 abstract 1
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Ultra Sonic Daignosis Equipment (AREA)

PCT/JP2002/008130 2001-08-10 2002-08-08 Medicaments combines d'agoniste de la gnrh WO2003015820A1 (fr)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
DE60239207T DE60239207D1 (de)	2001-08-10	2002-08-08	Gnrh-agonistische kombinationsmittel
US10/486,095 US20050215528A1 (en)	2001-08-10	2002-08-08	Gnrh agonist combination drugs
AT02758814T ATE498408T1 (de)	2001-08-10	2002-08-08	Gnrh-agonistische kombinationsmittel
EP02758814A EP1424080B1 (en)	2001-08-10	2002-08-08	Gnrh agonist combination drugs
CA2458452A CA2458452C (en)	2001-08-10	2002-08-08	Gnrh agonist combination drugs
US11/727,549 US20070179097A1 (en)	2001-08-10	2007-03-27	GnRH agonist combination drugs
US12/662,866 US20100286063A1 (en)	2001-08-10	2010-05-07	GNRH agonist combination drugs

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001244616		2001-08-10
JP2001-244616		2001-08-10

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US11/727,549 Continuation US20070179097A1 (en)	2001-08-10	2007-03-27	GnRH agonist combination drugs

Publications (1)

Publication Number	Publication Date
WO2003015820A1 true WO2003015820A1 (fr)	2003-02-27

Family

ID=19074519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/008130 WO2003015820A1 (fr)	2001-08-10	2002-08-08	Medicaments combines d'agoniste de la gnrh

Country Status (7)

Country	Link
US (3)	US20050215528A1 (ja)
EP (1)	EP1424080B1 (ja)
JP (1)	JP2003137814A (ja)
AT (1)	ATE498408T1 (ja)
CA (1)	CA2458452C (ja)
DE (1)	DE60239207D1 (ja)
WO (1)	WO2003015820A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004000363A1 (ja) *	2002-06-25	2003-12-31	Takeda Pharmaceutical Company Limited	徐放性組成物の製造方法
WO2004100991A1 (en) *	2003-05-15	2004-11-25	Universite Catholique De Louvain	Use of endothelin-1 antagonists for improving cancer therapy
WO2005023264A1 (en) *	2003-09-05	2005-03-17	Astrazeneca Ab	Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
US7626020B2 (en)	2004-02-20	2009-12-01	Astrazeneca Ab	Protected forms of N-(3-methoxy-5-methylpiperazin-2-yl)-2-(4-[1,3,4,-oxadiazol-2-yl]phenyl)-pyridine-3-sulphonamide
US7700559B2 (en)	2003-04-04	2010-04-20	Medical Research Council	Gonadotropin releasing hormone analogues conjugates with steroid hormones
US7820679B2 (en)	2002-08-23	2010-10-26	Astrazeneca Ab	N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent
US8642079B2 (en)	2004-02-23	2014-02-04	Hormos Medical Corporation	Solid formulations of ospemifene
US11576891B2 (en)	2010-06-16	2023-02-14	Endorecherche, Inc.	Methods of treating or preventing estrogen-related diseases
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003137814A (ja) *	2001-08-10	2003-05-14	Takeda Chem Ind Ltd	ＧｎＲＨアゴニストの併用剤
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
BR0313405A (pt)	2002-08-12	2005-07-12	Takeda Pharmaceutical	Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto
JP2004344035A (ja) *	2003-05-21	2004-12-09	Kureha Chem Ind Co Ltd	担子菌の乾燥方法
US20070191311A1 (en) *	2004-01-30	2007-08-16	Shuichiro Kakimoto	P2x receptor inhibitor
WO2005105052A1 (en)	2004-05-04	2005-11-10	Hormos Medical Ltd.	Novel oral formulations of ospemifene
US8758821B2 (en) *	2004-05-04	2014-06-24	Hormos Medical Ltd.	Oral formulations of ospemifene
PT1753417E (pt) *	2004-06-07	2012-07-05	Univ Tennessee Res Foundation	Um modulador selectivo de receptor de androgénio e as suas utilizações medicinais
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
US20080171736A1 (en) *	2004-12-23	2008-07-17	Gregory Christopher W	Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2007030362A1 (en) *	2005-09-07	2007-03-15	Laboratoires Serono Sa.	Ikk inhibitors for the treatment of endometriosis
NZ570381A (en)	2006-02-09	2011-02-25	Daiichi Sankyo Co Ltd	Anti-cancer pharmaceutical composition
MX2009008660A (es) *	2007-02-14	2009-10-13	Hormos Medical Ltd	Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
WO2008099060A2 (en) *	2007-02-14	2008-08-21	Hormos Medical Ltd	Methods for the preparation of fispemifene from ospemifene
AU2008306245A1 (en) *	2007-09-11	2009-04-09	Mondobiotech Laboratories Ag	Use of IL-1 receptor peptide, alone or in combination with D-Ala-Gln-octadecyl ester, as a therapeutic agent
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
JP5937297B2 (ja) *	2010-03-01	2016-06-22	キヤノンアネルバ株式会社	金属窒化膜、該金属窒化膜を用いた半導体装置、および半導体装置の製造方法
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
MX375256B (es)	2012-07-13	2025-03-06	Gtx Inc	Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2014060639A1 (en)	2012-10-19	2014-04-24	Fermion Oy	A process for the preparation of ospemifene
EP3803866A4 (en)	2018-05-24	2022-03-16	Nureva Inc.	METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
US11690807B2 (en)	2018-05-24	2023-07-04	Celanese Eva Performance Polymers Llc	Implantable device for sustained release of a macromolecular drug compound
KR20210013089A (ko)	2018-05-24	2021-02-03	셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨	거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치

Citations (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4472382A (en) *	1979-09-21	1984-09-18	Roussel Uclaf	Treatment method
WO1986001105A1 (en) *	1984-08-02	1986-02-27	Fernand Labrie	Pharmaceutical composition for combination therapy of hormone dependent cancers
WO1997027863A1 (de) *	1996-01-29	1997-08-07	Schering Aktiengesellschaft	Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen
WO1997040846A1 (en) *	1996-04-30	1997-11-06	Takeda Chemical Industries, Ltd.	COMBINED USE OF GnRH AGONIST AND ANTAGONIST
WO1999054309A1 (en) *	1998-04-23	1999-10-28	Takeda Chemical Industries, Ltd.	Naphthalene derivatives, their production and use
WO2000003979A1 (de) *	1998-07-18	2000-01-27	Schering Aktiengesellschaft	Benzocycloheptene, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
WO2000007576A2 (en) *	1998-08-07	2000-02-17	Endorecherche, Inc.	INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
WO2001030764A1 (fr) *	1999-10-22	2001-05-03	Takeda Chemical Industries, Ltd.	Alcools de phenyl-1-(1h-imidazol-4-yl) substitues en position 1, procede de preparation et utilisation de ces derniers
WO2001077107A1 (en) *	2000-04-07	2001-10-18	Takeda Chemical Industries, Ltd.	Oxazole derivatives and their uses as tyrosine kinase inhibitors
JP2002080458A (ja) *	1999-10-22	2002-03-19	Takeda Chem Ind Ltd	１−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
JP2002234843A (ja) *	2000-12-08	2002-08-23	Takeda Chem Ind Ltd	３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP2002241377A (ja) *	2000-11-20	2002-08-28	Takeda Chem Ind Ltd	イミダゾール誘導体、その製造法および用途
JP2002241268A (ja) *	2000-12-11	2002-08-28	Takeda Chem Ind Ltd	水溶解性が改善された医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2438350C3 (de) *	1974-08-09	1979-06-13	Hoechst Ag, 6000 Frankfurt	Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US20020019346A1 (en) *	1997-05-21	2002-02-14	Children's Medical Center Corporation	Treatment of prostate cancer by inhibiting lyn tyrosine kinase
WO1999008668A2 (en) *	1997-08-15	1999-02-25	Cephalon, Inc.	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
NZ505651A (en) *	1998-01-16	2003-08-29	Takeda Chemical Industries Ltd	Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US20040127470A1 (en) *	1998-12-23	2004-07-01	Pharmacia Corporation	Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
AU2001269439A1 (en) *	2000-07-05	2002-01-14	Takeda Chemical Industries Ltd.	Medicinal preparations for treating sex hormone-dependent diseases
EP1382350A4 (en) *	2001-04-25	2006-01-04	Takeda Pharmaceutical	MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
US6872715B2 (en) *	2001-08-06	2005-03-29	Kosan Biosciences, Inc.	Benzoquinone ansamycins
JP2003137814A (ja) *	2001-08-10	2003-05-14	Takeda Chem Ind Ltd	ＧｎＲＨアゴニストの併用剤
WO2003041739A1 (en) *	2001-11-13	2003-05-22	Takeda Chemical Industries, Ltd.	Anticaner agents

2002
- 2002-08-08 JP JP2002231922A patent/JP2003137814A/ja active Pending
- 2002-08-08 US US10/486,095 patent/US20050215528A1/en not_active Abandoned
- 2002-08-08 AT AT02758814T patent/ATE498408T1/de not_active IP Right Cessation
- 2002-08-08 DE DE60239207T patent/DE60239207D1/de not_active Expired - Lifetime
- 2002-08-08 WO PCT/JP2002/008130 patent/WO2003015820A1/ja active Application Filing
- 2002-08-08 CA CA2458452A patent/CA2458452C/en not_active Expired - Fee Related
- 2002-08-08 EP EP02758814A patent/EP1424080B1/en not_active Expired - Lifetime
2007
- 2007-03-27 US US11/727,549 patent/US20070179097A1/en not_active Abandoned
2010
- 2010-05-07 US US12/662,866 patent/US20100286063A1/en not_active Abandoned

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4472382A (en) *	1979-09-21	1984-09-18	Roussel Uclaf	Treatment method
WO1986001105A1 (en) *	1984-08-02	1986-02-27	Fernand Labrie	Pharmaceutical composition for combination therapy of hormone dependent cancers
WO1997027863A1 (de) *	1996-01-29	1997-08-07	Schering Aktiengesellschaft	Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen
WO1997040846A1 (en) *	1996-04-30	1997-11-06	Takeda Chemical Industries, Ltd.	COMBINED USE OF GnRH AGONIST AND ANTAGONIST
WO1999054309A1 (en) *	1998-04-23	1999-10-28	Takeda Chemical Industries, Ltd.	Naphthalene derivatives, their production and use
WO2000003979A1 (de) *	1998-07-18	2000-01-27	Schering Aktiengesellschaft	Benzocycloheptene, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
WO2000007576A2 (en) *	1998-08-07	2000-02-17	Endorecherche, Inc.	INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
WO2001030764A1 (fr) *	1999-10-22	2001-05-03	Takeda Chemical Industries, Ltd.	Alcools de phenyl-1-(1h-imidazol-4-yl) substitues en position 1, procede de preparation et utilisation de ces derniers
JP2002080458A (ja) *	1999-10-22	2002-03-19	Takeda Chem Ind Ltd	１−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
WO2001077107A1 (en) *	2000-04-07	2001-10-18	Takeda Chemical Industries, Ltd.	Oxazole derivatives and their uses as tyrosine kinase inhibitors
JP2002241377A (ja) *	2000-11-20	2002-08-28	Takeda Chem Ind Ltd	イミダゾール誘導体、その製造法および用途
JP2002234843A (ja) *	2000-12-08	2002-08-23	Takeda Chem Ind Ltd	３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP2002241268A (ja) *	2000-12-11	2002-08-28	Takeda Chem Ind Ltd	水溶解性が改善された医薬組成物

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CALCIF. TISSUE. INT., vol. 65, no. 2, 1999, pages 152 - 155 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); BLACKLEDGE G.R.P. ET AL.: "Emerging drugs in prostate cancer", XP002960254, Database accession no. 1998:292127 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); SAKAMOTO S. ET AL.: "Prevention of osteopenia induced with a gonadotropin-releasing hormone agonist in rats", XP002960255, Database accession no. 252762 *
DOWLING A.J. ET AL.: "Systematic treatment for prostate cancer", CANCER TREATMENT REVIEWS, vol. 24, no. 4, 1998, pages 283 - 301, XP000910517 *
EMERGING DRUGS, vol. 3, 1998, pages 303 - 315 *
GAMBACCIANI M. ET AL.: "Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists", BONE AND MINERAL, vol. 26, no. 1, 1994, pages 19 - 26, XP002960252 *
GAMBACCIANI M. ET AL.: "Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRG-agonist", CALCIF. TISSUE INT., vol. 61, no. SUPPL. 1, 1997, pages S15 - S18, XP002960253 *
MICHAUD L.B. ET AL.: "Complete estrogen blockade for the treatment of metastatic and early breast cancer", DRUGS & AGING, vol. 16, no. 4, 2000, pages 261 - 271, XP002960248 *
MICHAUD L.B. ET AL.: "Endocrine therapy of metastatic breast cancer", SEMINARS IN BREAST DISEASE, vol. 3, no. 2, 2000, pages 100 - 111, XP002960247 *
MUKHERJEE T. ET AL.: "A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment", AM. J. OBSTET. GYNECOL., vol. 175, no. 1, 1993, pages 105 - 109, XP002960251 *
PICKERSGILL A.: "GnRH agonists and add-back therapy: is there a perfect combination?", BR. J. OBSTET. GYNECOL., vol. 105, no. 5, 1998, pages 475 - 485, XP002960249 *
SURREY E.S. ET AL.: "Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: A preliminary report", OBSTETETRICS AND GYNECOLOGY, vol. 81, no. 4, 1993, pages 581 - 586, XP002960250 *
TRAYNOR A.: "Recent advances in hormonal therapy for cancer", CURRENT OPINION IN ONCOLOGY, vol. 7, no. 6, 1995, pages 572 - 581, XP000574188 *
YAHALOM D. ET AL.: "Hexapeptide and cylic pentapeptide endothelin antagonists directly activate pituitary gonadotropin-releasing hormone receptors", MOL. PHARM., vol. 57, no. 4, 2000, pages 718 - 724, XP002960256 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004000363A1 (ja) *	2002-06-25	2003-12-31	Takeda Pharmaceutical Company Limited	徐放性組成物の製造方法
US8088726B2 (en)	2002-06-25	2012-01-03	Takeda Pharmaceutical Company Limited	Process for producing sustained-release composition
US7820679B2 (en)	2002-08-23	2010-10-26	Astrazeneca Ab	N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent
US7700559B2 (en)	2003-04-04	2010-04-20	Medical Research Council	Gonadotropin releasing hormone analogues conjugates with steroid hormones
WO2004100991A1 (en) *	2003-05-15	2004-11-25	Universite Catholique De Louvain	Use of endothelin-1 antagonists for improving cancer therapy
WO2005023264A1 (en) *	2003-09-05	2005-03-17	Astrazeneca Ab	Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
AU2004269956B2 (en) *	2003-09-05	2008-04-17	Astrazeneca Ab	Combination comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)pyridine-3-sulphonamide and an LHRH analogue and/or a bisphosphonate
EP2018865A3 (en) *	2003-09-05	2009-11-18	AstraZeneca AB	Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
US7626020B2 (en)	2004-02-20	2009-12-01	Astrazeneca Ab	Protected forms of N-(3-methoxy-5-methylpiperazin-2-yl)-2-(4-[1,3,4,-oxadiazol-2-yl]phenyl)-pyridine-3-sulphonamide
US8642079B2 (en)	2004-02-23	2014-02-04	Hormos Medical Corporation	Solid formulations of ospemifene
US11576891B2 (en)	2010-06-16	2023-02-14	Endorecherche, Inc.	Methods of treating or preventing estrogen-related diseases
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Also Published As

Publication number	Publication date
DE60239207D1 (de)	2011-03-31
EP1424080B1 (en)	2011-02-16
EP1424080A1 (en)	2004-06-02
US20050215528A1 (en)	2005-09-29
US20100286063A1 (en)	2010-11-11
ATE498408T1 (de)	2011-03-15
CA2458452C (en)	2011-04-19
JP2003137814A (ja)	2003-05-14
CA2458452A1 (en)	2003-02-27
EP1424080A4 (en)	2004-09-01
US20070179097A1 (en)	2007-08-02

Legal Events

Date	Code	Title	Description
2003-02-27	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM
2003-02-27	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-03-27	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-04-23	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-02-06	WWE	Wipo information: entry into national phase	Ref document number: 10486095 Country of ref document: US
2004-02-09	WWE	Wipo information: entry into national phase	Ref document number: 2458452 Country of ref document: CA
2004-02-12	WWE	Wipo information: entry into national phase	Ref document number: 2002758814 Country of ref document: EP
2004-06-02	WWP	Wipo information: published in national office	Ref document number: 2002758814 Country of ref document: EP
2004-06-24	REG	Reference to national code	Ref country code: DE Ref legal event code: 8642
2004-12-14	NENP	Non-entry into the national phase	Ref country code: JP

Publication	Publication Date	Title
WO2003015820A1 (fr)	2003-02-27	Medicaments combines d'agoniste de la gnrh
Dorai et al.	2000	Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein
HUP0302544A3 (en)	2012-09-28	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AP2004002982A0 (en)	2004-03-31	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
MXPA04003668A (es)	2004-07-22	Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
UA86587C2 (ru)	2009-05-12	Лечение ревматоидного артрита с применением антитела против рецептора il-6 и метотрексата
HUP0600103A2 (en)	2006-06-28	Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
TNSN07161A1 (en)	2008-11-21	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
HUP0202708A3 (en)	2004-12-28	Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
GEP20063741B (en)	2006-02-10	Nonaryl-Heterocyclic NMDA/NR2B Antagonists
TW200730168A (en)	2007-08-16	Combination of an H3 antagonist/inverse agonist and an appetite suppressant
PL376258A1 (en)	2005-12-27	Methods and dosage forms for controlled delivery of paliperidone
TW200510328A (en)	2005-03-16	5-membered heterocycle-based p38 kinase inhibitors
AU2003256410A8 (en)	2004-02-25	Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions
IL179206A0 (en)	2007-03-08	Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
IL162862A (en)	2011-04-28	Short-acting sedative hypnotic agents for anesthesia and sedation and pharmaceutical compositions containing them
HK1086548A1 (en)	2006-09-22	Deuterated catecholamine derivatives and medicaments comprising said compounds
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1539156B8 (en)	2013-02-06	Liquid dosage forms of acid labile drugs
TW200507829A (en)	2005-03-01	New combination
MXPA05009135A (es)	2005-10-20	Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
WO2003068157A3 (en)	2004-03-04	Kinase inhibitors and methods of use thereof
HRPK20030525B1 (en)	2004-08-31	Bottle cap - container and dosage device of ingredients for quick preparation of beverages
PL1778622T3 (pl)	2010-06-30	Para-alkilo-podstawione amidy kwasu N-(hydroksy-3-metoksybenzylo)-cynamonowego i ich zastosowanie do wytwarzania środków leczniczych
ZA200403530B (en)	2005-07-28	Chemokine receptor antagonists and methods of use thereof.